全文获取类型
收费全文 | 13794篇 |
免费 | 2933篇 |
国内免费 | 84篇 |
专业分类
耳鼻咽喉 | 204篇 |
儿科学 | 379篇 |
妇产科学 | 395篇 |
基础医学 | 990篇 |
口腔科学 | 174篇 |
临床医学 | 2500篇 |
内科学 | 3118篇 |
皮肤病学 | 502篇 |
神经病学 | 1250篇 |
特种医学 | 432篇 |
外科学 | 2630篇 |
综合类 | 123篇 |
一般理论 | 9篇 |
预防医学 | 1697篇 |
眼科学 | 625篇 |
药学 | 646篇 |
中国医学 | 7篇 |
肿瘤学 | 1130篇 |
出版年
2024年 | 88篇 |
2023年 | 708篇 |
2022年 | 125篇 |
2021年 | 364篇 |
2020年 | 464篇 |
2019年 | 251篇 |
2018年 | 795篇 |
2017年 | 824篇 |
2016年 | 730篇 |
2015年 | 711篇 |
2014年 | 937篇 |
2013年 | 1043篇 |
2012年 | 734篇 |
2011年 | 739篇 |
2010年 | 784篇 |
2009年 | 916篇 |
2008年 | 711篇 |
2007年 | 681篇 |
2006年 | 686篇 |
2005年 | 626篇 |
2004年 | 579篇 |
2003年 | 508篇 |
2002年 | 510篇 |
2001年 | 158篇 |
2000年 | 94篇 |
1999年 | 156篇 |
1998年 | 207篇 |
1997年 | 218篇 |
1996年 | 176篇 |
1995年 | 143篇 |
1994年 | 126篇 |
1993年 | 103篇 |
1992年 | 81篇 |
1991年 | 67篇 |
1990年 | 58篇 |
1989年 | 87篇 |
1988年 | 80篇 |
1987年 | 56篇 |
1986年 | 48篇 |
1985年 | 42篇 |
1984年 | 50篇 |
1983年 | 47篇 |
1982年 | 61篇 |
1981年 | 44篇 |
1980年 | 39篇 |
1979年 | 24篇 |
1978年 | 23篇 |
1977年 | 16篇 |
1976年 | 13篇 |
1975年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
2.
3.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study
下载免费PDF全文
![点击此处可从《Journal of clinical nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
4.
5.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
6.
Evaluation of training nurses to perform semi‐automated three‐dimensional left ventricular ejection fraction using a customised workstation‐based training protocol
下载免费PDF全文
![点击此处可从《Journal of clinical nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
7.
Nickel Allergy and Our Children's Health: A Review of Indexed Cases and a View of Future Prevention
下载免费PDF全文
![点击此处可从《Pediatric dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Sharon E. Jacob M.D. Alina Goldenberg M.D. M.A.S. Janice L. Pelletier M.D. Luz S. Fonacier M.D. Richard Usatine M.D. Nanette Silverberg M.D. 《Pediatric dermatology》2015,32(6):779-785
Nickel is the leading cause of allergic contact dermatitis (ACD) from early childhood through adolescence. Studies have shown that skin piercings and other nickel‐laden exposures can trigger the onset of nickel ACD in those who are susceptible. Nickel ACD causes a vast amount of cutaneous disease in children. Cases of nickel ACD in children have been reported in peer‐reviewed literature from 28 states. Common items that contain inciting nickel include jewelry, coins, zippers, belts, tools, toys, chair studs, cases for cell phones and tablets, and dental appliances. The diagnosis of nickel ACD has been routinely confirmed by patch testing in children older than 6 months suspected of ACD from nickel. Unlike in Europe, there are no mandatory restrictions legislated for nickel exposure in the United States. Denmark has demonstrated that regulation of the nickel content in metals can lower the risk of ACD and the associated health care–related costs that arise from excess nickel exposure. To further awareness, this article reviews the prominent role of nickel in pediatric skin disease in the United States. It discusses the need for a campaign by caretakers to reduce nickel‐related morbidity. Lastly, it promotes the model of European legislation as a successful intervention in the prevention of nickel ACD. 相似文献
8.
9.
10.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255